A Phase 3 interventional study of Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg and Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 22 sites in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-03.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 26th largest by enrollment, is one of 5 that started in 2005, is one of 11 in phase 3, and was the 21st registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2005, is one of 7 in phase 3, and was the 16th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV). It will also compare PEG-IFN alfa 2a treatment alone and in combination with lamivudine (LAM). The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg · Drug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg
Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).
Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg · Drug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg · Drug: Lamivudine (LAM)
PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
Also known as: Pegasys®
PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
Also known as: Pegasys®
Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period
Combined response was defined as alanine aminotransferase (ALT) normalization plus lowering of hepatitis B virus (HBV) deoxyribo nucleic acid (DNA) levels to \<20,000 copies/mL (\<3,400 IU/mL) and was measured at the end of the 48-week follow-up period. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.
Time frame: At the end of the 48-week follow-up period at Week 144
Percentage of Participants Achieving the Combined Response at the End of Treatment
Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing end of treatment measurements, the next available post-treatment value was used.
Time frame: At end of treatment at Week 48 or 96 depending on the study arm
Percentage of Participants Achieving the Combined Response at 24 Weeks of Follow-up
Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used.
Time frame: At the end of 24 weeks of follow-up at Week 120
Percentage of Participants Achieving Combined Response Using a Cut-Off for HBV-DNA Levels to 2,000 IU/mL
Combined response was defined here as ALT normalization plus lowering HBV-DNA levels to a cutt-off \<2,000 IU/mL. In case of missing end of treatment measurements, the next available post-treatment value was used. In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.
Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Percentage of Participants Achieving Histological Response
Histological response was defined as an improvement by \>/= 2 in the Necroinflammatory Grading and/or by an improvement by \>/= 1 score in Fibrosis Staging according to Ishak. Necroinflammatory Grading ranges 0-14 and is the combined score for necrosis, range 0-10 and inflammation, range 0-4. The participant is scored for only one inflammatory condition. A higher score indicates worse condition. Fibrosis Staging according to Ishak ranges 0-6 and a higher score indicates greater fibrosis.
Time frame: At the end of the 48-week follow-up period at Week 144
Change From Baseline of Quantitative Hepatitis B Surface Antigen (HbsAg) Level at the End of Treatment
Time frame: At the end of treatment at Week 48 or 96 depending on the study arm
Percentage of Participants With Lamivudine Genotype Resistance During PEG-IFN+LAM96 Combined Therapy
Lamivudine resistance mutations were assessed by detection of the following mutations: rtL80V, rtL80I, rtV173G, rtV173L, rtL180M, rtA181T, rtA181V, rtM204V, rtM204I and rtN236T.
Time frame: At the end of the treatment period at Week 96
Percentage of Participants With ALT Normalization
Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Percentage of Participants With HBV-DNA Lowering to <3,400 IU/mL and to < 2,000 IU/mL
Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Percentage of Participants With HBV-DNA Below Limit of Quantification
HBV-DNA limit \< 6 IU/mL was defined as below quantification.
Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
Percentage of Participants With Loss of Hepatitis B Surface Antigen (HbsAg) and Hepatitis B Surface Antibodies (Anti-HBs) Seroconversion
This outcome measure presents percentage of participants with a combined response of HBsAg \< 5 IU/mL and anti-HBs positive. Positive anti-HBs represents antibodies produced against Hepatitis B Surface Antigen (HBsAg) and is an indication of recovery and immunity from HBV infection.
Time frame: At end of treatment at Week 48 or 96 depending on the study arm, at the end of 24 weeks of follow-up at Week 120 and at the end of the follow-up period at Week 144
| Milestone | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| Started | 51 | 52 | 25 |
| Completed | 41 | 40 | 17 |
| Not completed | 10 | 12 | 8 |
| Withdrew: Adverse event | 8 | 6 | 6 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 |
| Withdrew: Non study compliance | 0 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 2 | 0 |
Combined response was defined as alanine aminotransferase (ALT) normalization plus lowering of hepatitis B virus (HBV) deoxyribo nucleic acid (DNA) levels to \<20,000 copies/mL (\<3,400 IU/mL) and was measured at the end of the 48-week follow-up period. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period | 11.8 | 25.0 | 20.0 |
Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing end of treatment measurements, the next available post-treatment value was used.
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| Percentage of Participants Achieving the Combined Response at the End of Treatment | 29.4 | 38.5 | 32.0 |
Combined response was defined as ALT normalization plus lowering of HBV-DNA levels to \<20,000 copies/mL (\<3,400 IU/mL). In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used.
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| Percentage of Participants Achieving the Combined Response at 24 Weeks of Follow-up | 23.5 | 28.8 | 24.0 |
Combined response was defined here as ALT normalization plus lowering HBV-DNA levels to a cutt-off \<2,000 IU/mL. In case of missing end of treatment measurements, the next available post-treatment value was used. In case of missing week-24 post-treatment measurements, the nearest value with respect to the schedule time point in the time window 12 weeks post treatment until study end was used. Participants with missing 48 weeks follow-up measurements were considered as non-responders. However, if the scheduled 48-weeks post-treatment tests were performed earlier or later than 48 weeks post-treatment, but not earlier than 36 weeks post-treatment, the corresponding results were considered to determine response.
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| End of treatment | 29.4 | 38.5 | 28.0 |
| 24 weeks of follow-up | 21.6 | 26.9 | 20.0 |
| 48 weeks of follow-up | 11.8 | 23.1 | 20.0 |
Histological response was defined as an improvement by \>/= 2 in the Necroinflammatory Grading and/or by an improvement by \>/= 1 score in Fibrosis Staging according to Ishak. Necroinflammatory Grading ranges 0-14 and is the combined score for necrosis, range 0-10 and inflammation, range 0-4. The participant is scored for only one inflammatory condition. A higher score indicates worse condition. Fibrosis Staging according to Ishak ranges 0-6 and a higher score indicates greater fibrosis.
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| Percentage of Participants Achieving Histological Response | 13.7 | 5.8 | 8.0 |
| IU/mL | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| Baseline (n=51, 51, 25) | 9642.6 ± 19756.4 | 7229.8 ± 6459.0 | 8981.0 ± 7728.5 |
| Change from baseline (n=44, 44, 20) | -2801.1 ± 14691.2 | -2282.1 ± 6007.1 | -3121.2 ± 7128.9 |
Lamivudine resistance mutations were assessed by detection of the following mutations: rtL80V, rtL80I, rtV173G, rtV173L, rtL180M, rtA181T, rtA181V, rtM204V, rtM204I and rtN236T.
| percentage of participants | PEG-IFN+LAM96 |
|---|---|
| Percentage of Participants With Lamivudine Genotype Resistance During PEG-IFN+LAM96 Combined Therapy | 0 |
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| End of treatment | 35.3 | 40.4 | 40.0 |
| 24 weeks of follow-up | 45.1 | 46.2 | 40.0 |
| 48 weeks of follow-up | 35.3 | 34.6 | 36.0 |
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| End of treatment: HBV-DNA < 3,400 IU/mL | 60.8 | 67.3 | 76.0 |
| 24 weeks of follow-up: HBV-DNA < 3,400 IU/mL | 23.5 | 30.8 | 24.0 |
| 48 weeks of follow-up: HBV-DNA < 3,400 IU/mL | 11.8 | 30.8 | 20.0 |
| End of treatment: HBV-DNA < 2,000 IU/mL | 58.8 | 67.3 | 72.0 |
| 24 weeks of follow-up: HBV-DNA < 2,000 IU/mL | 21.6 | 28.8 | 20.0 |
| 48 weeks of follow-up: HBV-DNA < 2,000 IU/mL | 11.8 | 28.8 | 20.0 |
HBV-DNA limit \< 6 IU/mL was defined as below quantification.
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| End of treatment | 17.6 | 30.8 | 24.0 |
| 24 weeks of follow-up | 0.0 | 7.7 | 4.0 |
| 48 weeks of follow-up | 2.0 | 7.7 | 8.0 |
This outcome measure presents percentage of participants with a combined response of HBsAg \< 5 IU/mL and anti-HBs positive. Positive anti-HBs represents antibodies produced against Hepatitis B Surface Antigen (HBsAg) and is an indication of recovery and immunity from HBV infection.
| percentage of participants | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 |
|---|---|---|---|
| End of treatment | 2.0 | 3.8 | 0.0 |
| 24 weeks of follow-up | 0.0 | 5.8 | 0.0 |
| 48 weeks of follow-up | 0.0 | 7.7 | 0.0 |
Collected over Up to 48 weeks after last study treatment dose (up to Week 144). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN48 | — | 7/50 (14%) | 25/50 (50%) |
| PEG-IFN96 | — | 3/52 (5.8%) | 27/52 (51.9%) |
| PEG-IFN + LAM96 | — | 6/25 (24%) | 13/25 (52%) |
| Event | PEG-IFN48 | PEG-IFN96 | PEG-IFN + LAM96 |
|---|---|---|---|
| Infected cystInfections and infestations | 0/50 | 0/52 | 1/25 |
| Guillain-Barre syndromeNervous system disorders | 0/50 | 0/52 | 1/25 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/50 | 0/52 | 1/25 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/50 | 0/52 | 1/25 |
| Meniscus lesionInjury, poisoning and procedural complications | 0/50 | 0/52 | 1/25 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/50 | 0/52 | 1/25 |
| Hypertensive crisisVascular disorders | 0/50 | 0/52 | 1/25 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/50 | 0/52 | 0/25 |
| DiarrhoeaGastrointestinal disorders | 1/50 | 0/52 | 0/25 |
| PyrexiaGeneral disorders | 1/50 | 0/52 | 0/25 |
| Event | PEG-IFN48 | PEG-IFN96 | PEG-IFN + LAM96 |
|---|---|---|---|
| AstheniaGeneral disorders | 17/50 | 19/52 | 11/25 |
| PyrexiaGeneral disorders | 18/50 | 19/52 | 8/25 |
| HeadacheNervous system disorders | 13/50 | 8/52 | 7/25 |
| NeutropeniaBlood and lymphatic system disorders | 12/50 | 9/52 | 3/25 |
| Influenza like illnessGeneral disorders | 9/50 | 10/52 | 4/25 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/50 | 8/52 | 4/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/50 | 6/52 | 1/25 |
| Abdominal painGastrointestinal disorders | 4/50 | 4/52 | 3/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/50 | 6/52 | 3/25 |
| PruritusSkin and subcutaneous tissue disorders | 5/50 | 6/52 | 3/25 |
The ITT population included all participants randomized who received at least one dose of study medication.
| Age, Continuous(years) | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 | Total |
|---|---|---|---|---|
| Mean | 45.1 ± 10.2 | 44.1 ± 10.4 | 45.6 ± 8.6 | 44.6 ± 9.9 |
| Sex: Female, Male(Participants) | PEG-IFN48 | PEG-IFN96 | PEG-IFN+LAM96 | Total |
|---|---|---|---|---|
| Female | 18 | 7 | 7 | 32 |
| Male | 33 | 45 | 18 | 96 |
The record gives a start of Feb 2005, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a